PharmAla to supply Amsterdam UMC with LaNeo MDMA and develop single-capsule stability data

PharmAla Biotech Holdings Inc. (MDMA) — PharmAla Biotech signed a binding agreement to supply LaNeo 40 mg MDMA capsules to Amsterdam University Medical Center for a planned clinical trial, bundled with a three-year stability-testing program for its single-capsule format.

The company said the new stability data will support commercial-grade blister packaging for its LaNeo MDMA line. The deal extends PharmAla's footprint as a clinical-grade MDMA supplier into European research.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.